Stock Scorecard



Stock Summary for Centessa Pharmaceuticals plc (CNTA) - $14.43 as of 7/11/2025 8:14:16 PM EST

Total Score

7 out of 30

Safety Score

36 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CNTA

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CNTA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CNTA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CNTA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CNTA (36 out of 100)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for CNTA

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 ( OX2R ) Agonist 7/4/2025 7:00:00 AM
Centessa Pharmaceuticals ( CNTA ) Upgraded to Buy: What Does It Mean for the Stock? 6/16/2025 4:00:00 PM
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application ( IND ) for ORX142, a Novel Orexin Receptor 2 ( OX2R ) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year 6/16/2025 1:00:00 PM
Wall Street Analysts Think Centessa Pharmaceuticals ( CNTA ) Could Surge 138.77%: Read This Before Placing a Bet 6/4/2025 1:55:00 PM
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences 5/19/2025 12:00:00 PM
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - InflaRx ( NASDAQ:IFRX ) , Centessa Pharmaceuticals ( NASDAQ:CNTA ) 5/8/2025 2:42:00 PM
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - GlycoMimetics ( NASDAQ:GLYC ) 4/3/2025 11:30:00 AM
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 3/24/2025 11:00:00 AM
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 ( OX2R ) agonist, at the American Academy of Neurology ( AAN ) 2025 Annual Meeting - Centessa Pharmaceuticals ( NASDAQ:CNTA ) 3/6/2025 9:14:00 PM
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 ( OX2R ) agonist, at the American Academy of Neurology ( AAN ) 2025 Annual Meeting 3/6/2025 9:14:00 PM

Financial Details for CNTA

Company Overview

Ticker CNTA
Company Name Centessa Pharmaceuticals plc
Country USA
Description Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers drugs that change and improve the lives of patients. The company is headquartered in Cambridge, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date 8/18/2025

Stock Price History

Last Day Price 14.43
Price 4 Years Ago 11.26
Last Day Price Updated 7/11/2025 8:14:16 PM EST
Last Day Volume 460,489
Average Daily Volume 1,093,125
52-Week High 19.09
52-Week Low 9.00
Last Price to 52 Week Low 60.33%

Valuation Measures

Trailing PE N/A
Industry PE 22.40
Sector PE 41.70
5-Year Average PE -17.29
Free Cash Flow Ratio 18.27
Industry Free Cash Flow Ratio 18.02
Sector Free Cash Flow Ratio 33.25
Current Ratio Most Recent Quarter 14.37
Total Cash Per Share 0.79
Book Value Per Share Most Recent Quarter 2.89
Price to Book Ratio 4.85
Industry Price to Book Ratio 34.60
Sector Price to Book Ratio 31.09
Price to Sales Ratio Twelve Trailing Months 124.98
Industry Price to Sales Ratio Twelve Trailing Months 120.05
Sector Price to Sales Ratio Twelve Trailing Months 35.30
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 133,619,000
Market Capitalization 1,928,122,170
Institutional Ownership 94.42%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -56.04%
Reported EPS 12 Trailing Months -1.88
Reported EPS Past Year -0.20
Reported EPS Prior Year -1.99
Net Income Twelve Trailing Months -223,846,000
Net Income Past Year -235,757,000
Net Income Prior Year -151,085,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -205.20%

Balance Sheet

Total Cash Most Recent Quarter 105,156,000
Total Cash Past Year 383,221,000
Total Cash Prior Year 128,030,000
Net Cash Position Most Recent Quarter -4,096,000
Net Cash Position Past Year 274,281,000
Long Term Debt Past Year 108,940,000
Long Term Debt Prior Year 75,700,000
Total Debt Most Recent Quarter 109,252,000
Equity to Debt Ratio Past Year 0.79
Equity to Debt Ratio Most Recent Quarter 0.78
Total Stockholder Equity Past Year 401,545,000
Total Stockholder Equity Prior Year 236,244,000
Total Stockholder Equity Most Recent Quarter 386,247,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -177,890,712
Free Cash Flow Per Share Twelve Trailing Months -1.33
Free Cash Flow Past Year -142,089,000
Free Cash Flow Prior Year -160,511,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.29
MACD Signal 0.18
20-Day Bollinger Lower Band 10.47
20-Day Bollinger Middle Band 13.60
20-Day Bollinger Upper Band 16.73
Beta 1.49
RSI 59.56
50-Day SMA 14.81
150-Day SMA 9.21
200-Day SMA 9.31

System

Modified 7/10/2025 9:12:30 PM EST